Brought to you by 
Dendreon follow-on nets $197.4mm
May 2009
Executive Summary
Oncology therapeutics company Dendreon closed the second largest follow-on public offering so far this year, netting $197.4mm through the sale of 10.7mm common shares at $19.20 apiece. The company will put some of the proceeds towards continued development and eventual launch of its lead candidate Provenge, which just proved a prolonged survival rate in Phase III clinical trials of men with advanced prostate cancer.
Deal Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dendreon follow-on nets $197.4mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice